Boehringer Ingelheim before profit decline due to research spending

For 2022, however, Boehringer expects a slightly lower operating result due to the increased investments in research and development. Last year it rose to 4.7 (2020: 4.6) billion euros. Adjusted for currency and special effects, revenues should increase slightly. Uncertainty was caused by the ongoing corona pandemic, the disruptions in global supply chains, geopolitical tensions in Europe and an increasingly difficult industrial environment.

Significant gains

Last year, the family company’s sales climbed by more than five percent to 20.4 billion euros. Boehringer benefited from significant increases in its diabetes drug Jardiance and the lung drug Ofev.

However, sales of veterinary medicines also increased significantly – especially in the pet sector, while the livestock business grew only moderately due to African swine fever. Thanks to strong demand, Boehringer also significantly expanded sales in the biopharmaceutical contract customer business. The bottom line is that the group earned 3.4 billion euros last year, an increase of a good eleven percent.

By Editor

Leave a Reply